COMPASS Pathways (NASDAQ:CMPS) Receives Sell (D-) Rating from Weiss Ratings

Key Points

• COMPASS Pathways saw its stock rated as "sell (D-)" by Weiss Ratings, contrasting with other analysts who maintain a generally positive outlook with multiple "buy" ratings.
• As of recent trading, COMPASS Pathways shares rose by 0.6%, reaching a price of $6.28, amidst a market capitalization of $602.50 million.
• Institutional investors own 46.19% of COMPASS Pathways, with notable increases in holdings from several hedge funds in the past quarters.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report)'s stock had its "sell (d-)" rating reissued by research analysts at Weiss Ratings in a report issued on Friday,Weiss Ratings reports.

Other research analysts also recently issued reports about the company. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $15.00 price target on shares of COMPASS Pathways in a research report on Friday, August 1st. BTIG Research upped their target price on shares of COMPASS Pathways from $7.00 to $14.00 and gave the company a "buy" rating in a research note on Monday, October 13th. Finally, HC Wainwright reduced their price target on shares of COMPASS Pathways from $45.00 to $40.00 and set a "buy" rating for the company in a report on Monday, August 4th. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, COMPASS Pathways currently has a consensus rating of "Moderate Buy" and a consensus price target of $16.00.

COMPASS Pathways Stock Up 0.6%

Shares of NASDAQ:CMPS traded up $0.04 on Friday, reaching $6.28. The company had a trading volume of 672,509 shares, compared to its average volume of 1,569,051. The stock has a market capitalization of $602.50 million, a P/E ratio of -3.41 and a beta of 2.21. The stock has a 50-day moving average price of $5.46 and a 200 day moving average price of $4.45. COMPASS Pathways has a twelve month low of $2.25 and a twelve month high of $7.09. The company has a quick ratio of 8.82, a current ratio of 8.82 and a debt-to-equity ratio of 0.16.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.01). On average, equities analysts expect that COMPASS Pathways will post -2.33 EPS for the current year.

Institutional Investors Weigh In On COMPASS Pathways

Several institutional investors and hedge funds have recently made changes to their positions in the company. CWM LLC increased its holdings in shares of COMPASS Pathways by 19.2% during the third quarter. CWM LLC now owns 15,650 shares of the company's stock worth $90,000 after buying an additional 2,525 shares in the last quarter. Flagship Harbor Advisors LLC raised its position in COMPASS Pathways by 27.7% in the 1st quarter. Flagship Harbor Advisors LLC now owns 14,446 shares of the company's stock valued at $41,000 after purchasing an additional 3,134 shares during the last quarter. Conservest Capital Advisors Inc. raised its position in COMPASS Pathways by 32.5% in the 2nd quarter. Conservest Capital Advisors Inc. now owns 20,363 shares of the company's stock valued at $57,000 after purchasing an additional 5,000 shares during the last quarter. GAMMA Investing LLC raised its holdings in shares of COMPASS Pathways by 93.6% in the first quarter. GAMMA Investing LLC now owns 10,349 shares of the company's stock valued at $30,000 after buying an additional 5,003 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its position in COMPASS Pathways by 46.7% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 18,272 shares of the company's stock worth $51,000 after buying an additional 5,817 shares in the last quarter. Institutional investors and hedge funds own 46.19% of the company's stock.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.